Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CORCEPT THERAPEUTICS INC Director's Dealing 2021

Oct 6, 2021

30681_dirs_2021-10-05_2fa41305-01b1-4905-8535-58be7242386e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CORCEPT THERAPEUTICS INC (CORT)
CIK: 0001088856
Period of Report: 2021-10-01

Reporting Person: Maduck Sean (Chief Commercial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-10-01 Common Stock M 24363 $3.29 Acquired 64387 Direct
2021-10-01 Common Stock S 24363 $20.0047 Disposed 40024 Direct
2021-10-05 Common Stock M 637 $3.29 Acquired 40661 Direct
2021-10-05 Common Stock S 637 $20.00 Disposed 40024 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-10-01 Stock Option (Right to Buy) $3.29 M 24363 Disposed 2025-02-18 Common Stock (24363) Direct
2021-10-05 Stock Option (Right to Buy) $3.29 M 637 Disposed 2025-02-18 Common Stock (637) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 10000 Indirect
Common Stock 10000 Indirect

Footnotes

F1: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction.

F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $20.00 to $20.05 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

F3: Represents the shares held by Duckhill Capital, LLC of which the reporting person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

F4: Represents the shares held by Sean and Molly Maduck Living Trust of which the reporting person is a co-trustee.

F5: Fully exercisable.